<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script>if(location.protocol!=="https:"&&location.hostname!=="localhost"&&location.hostname!=="127.0.0.1")location.replace("https://"+location.host+location.pathname+location.search+location.hash);</script>
<meta http-equiv="Content-Security-Policy" content="upgrade-insecure-requests">
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± Ne Kadar Etkili? | UzunYaÅŸa</title>
<meta name="description" content="WHO'nun yaptÄ±rdÄ±ÄŸÄ± 3 Cochrane derlemesi GLP-1 ilaÃ§larÄ±nÄ±n etkinlik ve gÃ¼venlik verilerini analiz ediyor. Tirzepatide %16, semaglutide %11 kilo kaybÄ± saÄŸlÄ±yor.">
<meta name="author" content="UzunYaÅŸa">
<link rel="canonical" href="https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html">
<!-- Open Graph -->
<meta property="og:title" content="WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± GerÃ§ekten Ne Kadar Etkili? | UzunYaÅŸa">
<meta property="og:description" content="WHO'nun yaptÄ±rdÄ±ÄŸÄ± 3 Cochrane derlemesi GLP-1 ilaÃ§larÄ±nÄ±n etkinlik ve gÃ¼venlik verilerini analiz ediyor. Tirzepatide %16, semaglutide %11 kilo kaybÄ±.">
<meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
<meta property="og:url" content="https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html">
<meta property="og:type" content="article">
<meta property="og:locale" content="tr_TR">
<meta property="article:published_time" content="2026-02-12">
<!-- Fonts -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&family=Playfair+Display:wght@400;500;600;700&display=swap" rel="stylesheet">
<!-- Styles -->
<link rel="preload" href="../../styles/main.css" as="style">
 <link rel="stylesheet" href="../../styles/main.css">
<link rel="stylesheet" href="../../styles/content-page.css">
<link rel="preload" href="../../styles/animations.css" as="style">
 <link rel="stylesheet" href="../../styles/animations.css">
<style>
/* ===== READING PROGRESS BAR ===== */
.blog-progress {
  position: fixed; top: 0; left: 0; width: 0%;
  height: 3px; z-index: 10001;
  background: linear-gradient(90deg, #0D7377, #14919B, #E8963E);
  transition: width 0.1s linear;
}

/* ===== BLOG HERO ===== */
.blog-hero {
  position: relative;
  min-height: 480px;
  display: flex;
  align-items: flex-end;
  overflow: hidden;
  margin-top: 70px;
}
.blog-hero-img {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  object-fit: cover;
}
.blog-hero-overlay {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  background: linear-gradient(180deg,
    rgba(25,81,87,0.3) 0%,
    rgba(25,81,87,0.55) 40%,
    rgba(15,61,66,0.88) 100%);
}
.blog-hero-content {
  position: relative; z-index: 2;
  max-width: 860px; margin: 0 auto;
  padding: 3rem 2rem 3.5rem;
  color: white;
}
.blog-hero-badge {
  display: inline-block;
  padding: 0.4rem 1rem;
  border-radius: 20px;
  font-size: 0.8rem; font-weight: 600;
  margin-bottom: 1.25rem;
  background: #3B82F6;
  color: white;
}
.blog-hero-title {
  font-family: 'Playfair Display', serif;
  font-size: clamp(2rem, 4vw, 2.8rem);
  font-weight: 600;
  line-height: 1.2;
  margin-bottom: 1rem;
  text-shadow: 0 2px 8px rgba(0,0,0,0.3);
}
.blog-hero-subtitle {
  font-size: 1.15rem;
  opacity: 0.9;
  max-width: 640px;
  line-height: 1.7;
  margin-bottom: 1.25rem;
}
.blog-hero-meta {
  display: flex; gap: 1.5rem; flex-wrap: wrap;
  font-size: 0.85rem; opacity: 0.8;
}
.blog-hero-meta span { display: flex; align-items: center; gap: 0.4rem; }

/* ===== ARTICLE BODY ===== */
.blog-article {
  max-width: 800px;
  margin: 0 auto;
  padding: 2.5rem 2rem 4rem;
}

/* ===== BREADCRUMB ===== */
.blog-breadcrumb {
  display: flex; align-items: center; gap: 0.5rem;
  font-size: 0.85rem; color: var(--text-light);
  margin-bottom: 2rem; flex-wrap: wrap;
}
.blog-breadcrumb a {
  color: var(--primary); text-decoration: none; font-weight: 500;
}
.blog-breadcrumb a:hover { text-decoration: underline; }

/* ===== TOC ===== */
.blog-toc {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border: 1px solid #e2e8f0;
  border-left: 4px solid var(--primary);
  border-radius: 0 16px 16px 0;
  padding: 1.75rem 2rem;
  margin-bottom: 2.5rem;
}
.blog-toc h4 {
  font-size: 0.9rem; font-weight: 700;
  text-transform: uppercase; letter-spacing: 0.06em;
  color: var(--primary); margin-bottom: 1rem;
}
.blog-toc ol {
  list-style: none; counter-reset: toc; margin: 0; padding: 0;
}
.blog-toc li { counter-increment: toc; margin-bottom: 0.4rem; }
.blog-toc li a {
  display: flex; align-items: center; gap: 0.6rem;
  text-decoration: none; color: #334155;
  font-size: 0.95rem; padding: 0.4rem 0.6rem;
  border-radius: 8px; transition: all 0.2s;
}
.blog-toc li a::before {
  content: counter(toc);
  display: inline-flex; align-items: center; justify-content: center;
  width: 26px; height: 26px;
  background: #e2e8f0; border-radius: 50%;
  font-size: 0.75rem; font-weight: 700; color: #475569;
  flex-shrink: 0; transition: all 0.2s;
}
.blog-toc li a:hover { background: rgba(13,115,119,0.08); color: var(--primary); }
.blog-toc li a:hover::before { background: var(--primary); color: white; }

/* ===== CONTENT STYLES ===== */
.blog-content p {
  font-size: 1.05rem; line-height: 1.8; margin-bottom: 1.5rem; color: var(--text-dark);
}
.blog-content h2 {
  font-size: 1.5rem; font-weight: 700; color: var(--primary);
  margin: 3rem 0 1.25rem; padding-top: 2rem;
  border-top: 1px solid var(--border);
  position: relative; padding-bottom: 0.75rem;
}
.blog-content h2::after {
  content: ''; position: absolute; bottom: 0; left: 0;
  width: 60px; height: 3px;
  background: linear-gradient(90deg, var(--primary), #10b981);
  border-radius: 2px;
}
.blog-content h2:first-of-type { border-top: none; padding-top: 0; margin-top: 0; }
.blog-content h3 {
  font-size: 1.2rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text-dark);
}
.blog-content ul, .blog-content ol {
  margin: 1.25rem 0; padding-left: 1.5rem;
}
.blog-content li { margin-bottom: 0.5rem; font-size: 1.02rem; line-height: 1.7; }
.blog-content strong { color: var(--text-dark); }
.blog-content a { color: var(--primary); text-decoration: underline; }

/* ===== INFO BOXES ===== */
.blog-box {
  padding: 1.5rem 1.75rem;
  border-radius: 0 14px 14px 0;
  margin: 2rem 0;
  border-left: 4px solid;
  position: relative;
  display: flex; gap: 1rem; align-items: flex-start;
}
.blog-box .box-icon {
  flex-shrink: 0; width: 28px; height: 28px; margin-top: 2px;
}
.blog-box .box-body { flex: 1; }
.blog-box .box-body strong { display: block; margin-bottom: 0.4rem; font-size: 0.95rem; }
.blog-box .box-body p, .blog-box .box-body ul { margin: 0; font-size: 0.95rem; line-height: 1.7; }
.blog-box .box-body ul { padding-left: 1.2rem; margin-top: 0.5rem; }
.blog-box .box-body li { margin-bottom: 0.3rem; }

.blog-box.info {
  background: linear-gradient(135deg, #eff6ff, #f0f9ff);
  border-left-color: #3B82F6;
}
.blog-box.info .box-icon { color: #3B82F6; }
.blog-box.warning {
  background: linear-gradient(135deg, #fef3c7, #fffbeb);
  border-left-color: #F59E0B;
}
.blog-box.warning .box-icon { color: #F59E0B; }
.blog-box.success {
  background: linear-gradient(135deg, #ecfdf5, #f0fdf4);
  border-left-color: #10B981;
}
.blog-box.success .box-icon { color: #10B981; }
.blog-box.danger {
  background: linear-gradient(135deg, #fef2f2, #fee2e2);
  border-left-color: #EF4444;
}
.blog-box.danger .box-icon { color: #EF4444; }
.blog-box.tip {
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
  border-left-color: #0D7377;
}
.blog-box.tip .box-icon { color: #0D7377; }

/* ===== KEY STAT BOX ===== */
.key-stat {
  display: flex; align-items: center; gap: 1.5rem;
  padding: 1.75rem 2rem;
  border-radius: 0 16px 16px 0;
  margin: 2rem 0;
  border-left: 5px solid var(--primary);
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
}
.key-stat .ks-num {
  font-size: 2.75rem; font-weight: 800; color: var(--primary);
  line-height: 1; white-space: nowrap;
}
.key-stat .ks-text { font-size: 0.95rem; color: #195157; line-height: 1.6; }
.key-stat.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
.key-stat.accent .ks-num { color: #E8963E; }
.key-stat.danger { border-left-color: #EF4444; background: linear-gradient(135deg, #fef2f2, #fee2e2); }
.key-stat.danger .ks-num { color: #EF4444; }

/* ===== STAT CARDS ===== */
.stat-cards {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
  gap: 1rem; margin: 2rem 0;
}
.stat-card {
  background: white;
  border: 1px solid var(--border);
  border-radius: 16px;
  padding: 1.5rem;
  text-align: center;
  transition: all 0.3s ease;
  position: relative; overflow: hidden;
}
.stat-card::before {
  content: ''; position: absolute; top: 0; left: 0; right: 0;
  height: 3px;
  background: linear-gradient(90deg, var(--primary), var(--accent));
}
.stat-card:hover { transform: translateY(-4px); box-shadow: 0 12px 30px rgba(0,0,0,0.1); }
.stat-card .sc-num {
  font-size: 2rem; font-weight: 800; color: var(--primary);
  margin-bottom: 0.25rem;
}
.stat-card .sc-label {
  font-size: 0.8rem; color: var(--text-light); line-height: 1.4;
}

/* ===== COMPARISON TABLE ===== */
.blog-table {
  width: 100%; border-collapse: collapse; margin: 2rem 0;
  font-size: 0.95rem; border-radius: 12px; overflow: hidden;
  border: 1px solid var(--border);
}
.blog-table th {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  padding: 1rem; text-align: left; font-weight: 600;
  color: var(--primary); border-bottom: 2px solid var(--primary);
}
.blog-table td {
  padding: 0.85rem 1rem; border-bottom: 1px solid var(--border);
}
.blog-table tr:hover td { background: rgba(13,115,119,0.03); }
.blog-table tr:last-child td { border-bottom: none; }

/* ===== SVG INFOGRAPHIC ===== */
.blog-infographic {
  margin: 2.5rem 0; padding: 2rem;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border: 1px solid #e2e8f0;
  text-align: center;
}
.blog-infographic svg { max-width: 100%; height: auto; }
.blog-infographic figcaption {
  margin-top: 1rem; font-size: 0.85rem;
  color: var(--text-light); font-style: italic;
}

/* ===== PULL QUOTE ===== */
.blog-quote {
  position: relative;
  padding: 2rem 2.5rem;
  margin: 2.5rem 0;
  font-size: 1.15rem; font-style: italic;
  color: #334155; line-height: 1.7;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border-left: 4px solid var(--primary);
}
.blog-quote::before {
  content: '\201C'; position: absolute; top: -8px; left: 16px;
  font-size: 4rem; color: rgba(13,115,119,0.12);
  font-family: Georgia, serif; line-height: 1;
}
.blog-quote cite {
  display: block; margin-top: 0.75rem;
  font-size: 0.9rem; font-style: normal;
  font-weight: 600; color: var(--primary);
}

/* ===== KEY TAKEAWAY ===== */
.blog-takeaway {
  background: linear-gradient(135deg, #195157, #2a6b73);
  color: white; padding: 2rem; border-radius: 16px;
  margin: 2.5rem 0; position: relative; overflow: hidden;
}
.blog-takeaway::before {
  content: ''; position: absolute; top: -30%; right: -10%;
  width: 200px; height: 200px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-takeaway h4 {
  font-size: 0.85rem; text-transform: uppercase;
  letter-spacing: 0.1em; opacity: 0.8; margin-bottom: 0.75rem;
}
.blog-takeaway ul { list-style: none; padding: 0; margin: 0; }
.blog-takeaway li {
  padding: 0.5rem 0 0.5rem 1.75rem; position: relative;
  font-size: 0.95rem; line-height: 1.6;
}
.blog-takeaway li::before {
  content: 'âœ“'; position: absolute; left: 0;
  color: #10b981; font-weight: 700;
}

/* ===== CTA BOX ===== */
.blog-cta {
  background: linear-gradient(135deg, var(--primary), #2a7d83);
  color: white; padding: 2.5rem; border-radius: 20px;
  text-align: center; margin: 3rem 0;
  position: relative; overflow: hidden;
}
.blog-cta::before {
  content: ''; position: absolute; top: -50%; right: -30%;
  width: 300px; height: 300px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-cta h3 { font-size: 1.5rem; font-weight: 700; margin-bottom: 0.75rem; }
.blog-cta p { opacity: 0.9; margin-bottom: 1.5rem; max-width: 400px; margin-left: auto; margin-right: auto; }
.blog-cta a {
  display: inline-block;
  background: white; color: var(--primary);
  padding: 0.875rem 2rem; border-radius: 10px;
  text-decoration: none; font-weight: 700; font-size: 1rem;
  transition: all 0.3s;
}
.blog-cta a:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 25px rgba(0,0,0,0.2);
}

/* ===== AUTHOR BOX ===== */
.blog-author {
  display: flex; align-items: center; gap: 1.25rem;
  padding: 1.75rem; background: white;
  border-radius: 16px; border: 1px solid var(--border);
  margin: 2.5rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.04);
}
.blog-author-avatar {
  width: 64px; height: 64px; border-radius: 50%;
  background: linear-gradient(135deg, var(--primary), var(--primary-light));
  display: flex; align-items: center; justify-content: center;
  color: white; font-weight: 700; font-size: 1.1rem;
  flex-shrink: 0;
}
.blog-author-info h4 { font-weight: 600; margin-bottom: 0.25rem; font-size: 1rem; }
.blog-author-info p { font-size: 0.85rem; color: var(--text-light); margin: 0; line-height: 1.5; }

/* ===== RELATED POSTS ===== */
.blog-related { margin: 3rem 0; }
.blog-related h3 {
  font-size: 1.25rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 1.5rem;
}
.related-grid {
  display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
  gap: 1.25rem;
}
.related-card {
  background: white; border: 1px solid var(--border);
  border-radius: 14px; overflow: hidden;
  text-decoration: none; color: inherit;
  transition: all 0.3s ease;
}
.related-card:hover {
  transform: translateY(-4px);
  box-shadow: 0 12px 30px rgba(0,0,0,0.1);
  border-color: var(--primary);
}
.related-card-img {
  height: 140px; background-size: cover; background-position: center;
  position: relative;
}
.related-card-img::after {
  content: ''; position: absolute; bottom: 0; left: 0; right: 0;
  height: 50%;
  background: linear-gradient(to top, rgba(0,0,0,0.4), transparent);
}
.related-card-body { padding: 1rem 1.25rem; }
.related-card-body h4 {
  font-size: 0.95rem; font-weight: 600; line-height: 1.4;
  margin-bottom: 0.5rem; color: var(--text-dark);
}
.related-card-body p {
  font-size: 0.8rem; color: var(--text-light); margin: 0;
}

/* ===== SOCIAL SHARING ===== */
.blog-share {
  display: flex; align-items: center; gap: 0.75rem;
  margin: 2rem 0; padding: 1.25rem 0;
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
}
.blog-share span { font-size: 0.9rem; font-weight: 600; color: var(--text-medium); }
.share-btn {
  display: inline-flex; align-items: center; justify-content: center;
  width: 40px; height: 40px; border-radius: 50%;
  border: 1px solid var(--border); background: white;
  color: var(--text-medium); text-decoration: none;
  transition: all 0.2s; cursor: pointer;
}
.share-btn:hover { border-color: var(--primary); color: var(--primary); background: rgba(13,115,119,0.05); }
.share-btn svg { width: 18px; height: 18px; }

/* ===== NEWSLETTER ===== */
.blog-newsletter {
  background: linear-gradient(135deg, var(--bg-cream), #f0f9ff);
  border: 2px solid var(--border);
  border-radius: 20px;
  padding: 2.5rem;
  text-align: center;
  margin: 3rem 0;
}
.blog-newsletter h3 {
  font-size: 1.3rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 0.5rem;
}
.blog-newsletter p {
  color: var(--text-medium); margin-bottom: 1.5rem; font-size: 0.95rem;
}
.newsletter-form {
  display: flex; max-width: 420px; margin: 0 auto; gap: 0.5rem;
}
.newsletter-form input {
  flex: 1; padding: 0.875rem 1rem;
  border: 1px solid var(--border); border-radius: 10px;
  font-size: 0.95rem; font-family: inherit;
}
.newsletter-form input:focus {
  outline: none; border-color: var(--primary);
  box-shadow: 0 0 0 3px rgba(13,115,119,0.1);
}
.newsletter-form button {
  background: var(--primary); color: white;
  padding: 0.875rem 1.5rem; border: none; border-radius: 10px;
  font-weight: 600; font-size: 0.95rem; cursor: pointer;
  transition: all 0.2s; font-family: inherit;
}
.newsletter-form button:hover {
  background: var(--primary-dark);
  transform: translateY(-1px);
}

/* ===== DISCLAIMER ===== */
.blog-disclaimer {
  font-size: 0.8rem; color: var(--text-light);
  margin-top: 2rem; padding-top: 1.5rem;
  border-top: 1px solid var(--border);
  line-height: 1.6;
}

/* ===== BAR CHART ===== */
.bar-chart { margin: 2.5rem 0; }
.bar-chart h4 { font-size: 1rem; font-weight: 700; color: var(--primary); margin-bottom: 1.25rem; }
.bar-row { display: flex; align-items: center; gap: 1rem; margin-bottom: 0.75rem; }
.bar-label { width: 120px; font-size: 0.85rem; font-weight: 600; color: var(--text-dark); flex-shrink: 0; }
.bar-track { flex: 1; height: 32px; background: #eef3f4; border-radius: 8px; overflow: hidden; }
.bar-fill {
  height: 100%; border-radius: 8px;
  display: flex; align-items: center; justify-content: flex-end;
  padding-right: 10px; font-size: 0.8rem; font-weight: 700; color: white;
  transform-origin: left; transform: scaleX(0);
  transition: transform 1s cubic-bezier(0.4,0,0.2,1);
}
.bar-fill.anim-visible { transform: scaleX(1); }
.bar-fill.clr-primary { background: linear-gradient(90deg, #0D7377, #14919B); }
.bar-fill.clr-accent { background: linear-gradient(90deg, #E8963E, #F5B06B); }
.bar-fill.clr-dark { background: linear-gradient(90deg, #195157, #2a7a82); }
.bar-fill.clr-gray { background: linear-gradient(90deg, #374151, #6B7280); }
.bar-fill.clr-success { background: linear-gradient(90deg, #059669, #10B981); }

/* ===== DONUT CHART ===== */
.donut-chart { display: flex; flex-wrap: wrap; align-items: center; justify-content: center; gap: 2rem; margin: 2.5rem 0; }
.donut-chart svg { max-width: 200px; }
.donut-legend { list-style: none; padding: 0; }
.donut-legend li { display: flex; align-items: center; gap: 0.6rem; margin-bottom: 0.5rem; font-size: 0.9rem; }
.donut-swatch { width: 14px; height: 14px; border-radius: 4px; flex-shrink: 0; }

/* ===== RESPONSIVE ===== */
@media (max-width: 768px) {
  .blog-hero { min-height: 380px; }
  .blog-hero-title { font-size: 1.8rem; }
  .blog-hero-content { padding: 2rem 1.5rem 2.5rem; }
  .blog-article { padding: 2rem 1.25rem 3rem; }
  .key-stat { flex-direction: column; text-align: center; padding: 1.5rem; }
  .key-stat .ks-num { font-size: 2rem; }
  .blog-author { flex-direction: column; text-align: center; }
  .stat-cards { grid-template-columns: repeat(2, 1fr); }
  .bar-label { width: 80px; font-size: 0.8rem; }
  .newsletter-form { flex-direction: column; }
  .related-grid { grid-template-columns: 1fr; }
  .blog-share { flex-wrap: wrap; }
}
</style>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± Ne Kadar Etkili? | UzunYaÅŸa",
  "description": "WHO",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-12",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@uzunyasaorg">
    <meta name="twitter:title" content="WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± Ne Kadar Etkili?">
    <meta name="twitter:description" content="WHO">
    <meta name="twitter:image" content="https://uzunyasa.com/images/og-default.png">
  </head>
<body>

<!-- Reading Progress Bar -->
<div class="blog-progress" id="blogProgress"></div>

<!-- HEADER -->
<header class="header">
  <div class="header-inner">
    <a href="../../index.html" class="logo">
      <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="logo-img">
    </a>
    <nav class="nav">
      <ul class="nav-links">
        <li class="nav-dropdown">
          <a href="#" class="nav-link">KeÅŸfet</a>
          <div class="nav-dropdown-content">
            <a href="../beslenme.html" class="nav-dropdown-item">Beslenme</a>
            <a href="../egzersiz.html" class="nav-dropdown-item">Egzersiz</a>
            <a href="../tedavi.html" class="nav-dropdown-item">Kilo YÃ¶netimi</a>
            <a href="../uyku-stres.html" class="nav-dropdown-item">Zihin & DavranÄ±ÅŸ</a>
          </div>
        </li>
        <li><a href="../blog.html" class="nav-link active">Blog</a></li>
        <li><a href="../araclar.html" class="nav-link">AraÃ§lar</a></li>
        <li><a href="../hikayeler.html" class="nav-link">Hikayeler</a></li>
        <li><a href="../bilim.html" class="nav-link">Bilim</a></li>
        <li><a href="../hakkimizda.html" class="nav-link">HakkÄ±mÄ±zda</a></li>
      </ul>
      <a href="../test.html" class="btn btn-primary">Teste BaÅŸla</a>
    </nav>
  </div>
</header>

<!-- HERO -->
<section class="blog-hero">
  <img class="blog-hero-img" src="https://images.unsplash.com/photo-1576091160550-2173dba999ef?w=1200&q=80" alt="WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ±">
  <div class="blog-hero-overlay"></div>
  <div class="blog-hero-content anim-slide-up anim-visible">
    <span class="blog-hero-badge">ğŸ”¬ Bilimsel AraÅŸtÄ±rma</span>
    <h1 class="blog-hero-title">WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± GerÃ§ekten Ne Kadar Etkili?</h1>
    <p class="blog-hero-subtitle">DÃ¼nya SaÄŸlÄ±k Ã–rgÃ¼tÃ¼'nÃ¼n yaptÄ±rdÄ±ÄŸÄ± 3 bÃ¼yÃ¼k Cochrane derlemesi, 44.000'den fazla katÄ±lÄ±mcÄ±yla GLP-1 ilaÃ§larÄ±nÄ±n etkinlik ve gÃ¼venlik profilini ortaya koyuyor. Peki rakamlar ne sÃ¶ylÃ¼yor?</p>
    <div class="blog-hero-meta">
      <span>ğŸ“… 12 Åubat 2026</span>
      <span>â± 12 dk okuma</span>
      <span>âœï¸ UzunYaÅŸa EditÃ¶ryal</span>
    </div>
  </div>
</section>

<!-- ARTICLE -->
<article class="blog-article">

  <!-- Breadcrumb -->
  <nav class="blog-breadcrumb" aria-label="Breadcrumb">
    <a href="../../index.html">Ana Sayfa</a>
    <span>â€º</span>
    <a href="../blog.html">Blog</a>
    <span>â€º</span>
    <span>WHO Cochrane GLP-1 Ä°ncelemesi</span>
  </nav>

  <!-- Table of Contents -->
  <div class="blog-toc anim-slide-up">
    <h4>ğŸ“‹ Ä°Ã§indekiler</h4>
    <ol>
      <li><a href="#bolum-1">Cochrane Nedir ve Bu Ä°nceleme Neden Ã–nemli?</a></li>
      <li><a href="#bolum-2">ÃœÃ§ Ä°laÃ§, ÃœÃ§ Derleme: Genel BakÄ±ÅŸ</a></li>
      <li><a href="#bolum-3">Tirzepatide: Åampiyonun Karnesi</a></li>
      <li><a href="#bolum-4">Semaglutide: En Ã‡ok Veri, En Ã‡ok Deneyim</a></li>
      <li><a href="#bolum-5">Liraglutide: Ä°lk KuÅŸaÄŸÄ±n Dersleri</a></li>
      <li><a href="#bolum-6">Yan Etkiler ve GÃ¼venlik Profili</a></li>
      <li><a href="#bolum-7">EndÃ¼stri SponsorluÄŸu Sorunu</a></li>
      <li><a href="#bolum-8">TÃ¼rkiye'de Durum Ne?</a></li>
      <li><a href="#bolum-9">SonuÃ§: Ne AnlamamÄ±z Gerekiyor?</a></li>
    </ol>
  </div>

  <!-- Content -->
  <div class="blog-content">

    <!-- Key stat opener -->
    <div class="key-stat anim-slide-up">
      <span class="ks-num">44.247</span>
      <span class="ks-text">WHO'nun yaptÄ±rdÄ±ÄŸÄ± 3 Cochrane derlemesinde toplam katÄ±lÄ±mcÄ± sayÄ±sÄ± â€” obezite tedavisinde ÅŸimdiye kadar yapÄ±lmÄ±ÅŸ en kapsamlÄ± baÄŸÄ±msÄ±z kanÄ±t deÄŸerlendirmesi.</span>
    </div>

    <p>Åubat 2026'da klinik beslenme ve obezite alanÄ±nda Ã¶nemli bir geliÅŸme yaÅŸandÄ±: <strong>DÃ¼nya SaÄŸlÄ±k Ã–rgÃ¼tÃ¼ (WHO)</strong> tarafÄ±ndan yaptÄ±rÄ±lan Ã¼Ã§ bÃ¼yÃ¼k Cochrane sistematik derlemesi yayÄ±nlandÄ±. Bu derlemeler, son yÄ±llarÄ±n en Ã§ok konuÅŸulan ilaÃ§ grubu olan <strong>GLP-1 reseptÃ¶r agonistlerinin</strong> (glukagon benzeri peptid-1) obezite tedavisindeki etkinliÄŸini, gÃ¼venliÄŸini ve kanÄ±t kalitesini mercek altÄ±na alÄ±yor.</p>

    <p>Cochrane derlemeleri, tÄ±p dÃ¼nyasÄ±nda "altÄ±n standart" olarak kabul edilir. Tek bir Ã§alÄ±ÅŸmanÄ±n sonuÃ§larÄ±na deÄŸil, konuyla ilgili yapÄ±lmÄ±ÅŸ <strong>tÃ¼m randomize kontrollÃ¼ Ã§alÄ±ÅŸmalarÄ±n</strong> sistematik analizine dayanÄ±r. WHO'nun bu derlemeleri yaptÄ±rmasÄ±nÄ±n nedeni aÃ§Ä±k: kÃ¼resel obezite kÄ±lavuzlarÄ±nÄ± ÅŸekillendirmek iÃ§in gÃ¼venilir, baÄŸÄ±msÄ±z kanÄ±ta ihtiyaÃ§ var.</p>

    <p>Peki bu Ã¼Ã§ dev derleme bize ne sÃ¶ylÃ¼yor? Gelin rakamlarÄ±, bulgularÄ± ve "ince yazÄ±larÄ±" birlikte inceleyelim.</p>

    <!-- ==================== BÃ–LÃœM 1 ==================== -->
    <h2 id="bolum-1">1. Cochrane Nedir ve Bu Ä°nceleme Neden Ã–nemli?</h2>

    <p><strong>Cochrane</strong>, 1993'ten bu yana tÄ±bbi kanÄ±tlarÄ± baÄŸÄ±msÄ±z olarak deÄŸerlendiren uluslararasÄ± bir kuruluÅŸtur. HiÃ§bir ilaÃ§ firmasÄ±ndan fon almaz; araÅŸtÄ±rmacÄ±larÄ± Ã§Ä±kar Ã§atÄ±ÅŸmasÄ± beyanÄ± vermek zorundadÄ±r. Bu nedenle Cochrane derlemeleri, klinik karar verme sÃ¼reÃ§lerinde en gÃ¼venilir kaynaklardan biri olarak kabul edilir.</p>

    <div class="blog-box info anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="16" x2="12" y2="12"/><line x1="12" y1="8" x2="12.01" y2="8"/></svg>
      <div class="box-body">
        <strong>Cochrane Derlemesi Nedir?</strong>
        <p>Bir konuda yapÄ±lmÄ±ÅŸ tÃ¼m randomize kontrollÃ¼ Ã§alÄ±ÅŸmalarÄ± (RKÃ‡) sistematik olarak toplayan, kalitesini deÄŸerlendiren ve istatistiksel olarak birleÅŸtiren bilimsel analiz yÃ¶ntemidir. Tek bir Ã§alÄ±ÅŸmaya gÃ¼venmek yerine, <strong>kanÄ±tÄ±n tamamÄ±na</strong> bakar.</p>
      </div>
    </div>

    <p>WHO'nun bu Ã¼Ã§ derlemeyi yaptÄ±rmasÄ±nÄ±n stratejik bir amacÄ± var: KuruluÅŸ, <strong>obezite tedavisine yÃ¶nelik yeni kÃ¼resel kÄ±lavuzlar</strong> hazÄ±rlÄ±yor. Bu kÄ±lavuzlar, Ã¶zellikle dÃ¼ÅŸÃ¼k ve orta gelirli Ã¼lkelerde ilaÃ§ eriÅŸimi, maliyet-etkinlik ve tedavi protokollerini belirleyecek. DolayÄ±sÄ±yla bu derlemeler sadece akademik deÄŸil, milyonlarca insanÄ±n tedavi seÃ§eneklerini doÄŸrudan etkileyecek.</p>

    <!-- ==================== BÃ–LÃœM 2 ==================== -->
    <h2 id="bolum-2">2. ÃœÃ§ Ä°laÃ§, ÃœÃ§ Derleme: Genel BakÄ±ÅŸ</h2>

    <p>Cochrane ekibi, Ã¼Ã§ farklÄ± GLP-1 reseptÃ¶r agonistini ayrÄ± ayrÄ± inceledi. Her biri iÃ§in ayrÄ± bir sistematik derleme hazÄ±rlandÄ±:</p>

    <!-- Stat Cards -->
    <div class="stat-cards anim-slide-up">
      <div class="stat-card">
        <div class="sc-num">8</div>
        <div class="sc-label">Tirzepatide RKÃ‡<br>(6.361 katÄ±lÄ±mcÄ±)</div>
      </div>
      <div class="stat-card">
        <div class="sc-num">18</div>
        <div class="sc-label">Semaglutide RKÃ‡<br>(27.949 katÄ±lÄ±mcÄ±)</div>
      </div>
      <div class="stat-card">
        <div class="sc-num">24</div>
        <div class="sc-label">Liraglutide RKÃ‡<br>(9.937 katÄ±lÄ±mcÄ±)</div>
      </div>
      <div class="stat-card">
        <div class="sc-num">50</div>
        <div class="sc-label">Toplam Ã‡alÄ±ÅŸma<br>SayÄ±sÄ±</div>
      </div>
    </div>

    <p>Bu Ã¼Ã§ ilaÃ§ da aynÄ± mekanizmayÄ± kullanÄ±r: doÄŸal olarak salgÄ±lanan GLP-1 hormonunu taklit ederek sindirim hÄ±zÄ±nÄ± yavaÅŸlatÄ±r, tokluk hissini artÄ±rÄ±r ve beyin-baÄŸÄ±rsak ekseninde iÅŸtahÄ± baskÄ±lar. Ancak etkinlikleri, uygulama ÅŸekilleri ve yan etki profilleri Ã¶nemli Ã¶lÃ§Ã¼de farklÄ±dÄ±r.</p>

    <!-- Comparison Table -->
    <table class="blog-table anim-slide-up">
      <thead>
        <tr>
          <th>Ã–zellik</th>
          <th>Tirzepatide</th>
          <th>Semaglutide</th>
          <th>Liraglutide</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td><strong>Ticari Adlar</strong></td>
          <td>Mounjaro, Zepbound</td>
          <td>Ozempic, Wegovy, Rybelsus</td>
          <td>Victoza, Saxenda</td>
        </tr>
        <tr>
          <td><strong>Uygulama</strong></td>
          <td>Haftada 1 enjeksiyon</td>
          <td>Haftada 1 enjeksiyon / Oral</td>
          <td>GÃ¼nlÃ¼k enjeksiyon</td>
        </tr>
        <tr>
          <td><strong>Mekanizma</strong></td>
          <td>GLP-1 + GIP Ã§ift agonist</td>
          <td>GLP-1 agonist</td>
          <td>GLP-1 agonist</td>
        </tr>
        <tr>
          <td><strong>Ort. Kilo KaybÄ±</strong></td>
          <td>~%16</td>
          <td>~%11</td>
          <td>~%5-8*</td>
        </tr>
        <tr>
          <td><strong>KanÄ±t SÃ¼resi</strong></td>
          <td>3,5 yÄ±la kadar</td>
          <td>2 yÄ±la kadar</td>
          <td>2 yÄ±la kadar</td>
        </tr>
      </tbody>
    </table>

    <!-- ==================== BÃ–LÃœM 3 ==================== -->
    <h2 id="bolum-3">3. Tirzepatide: Åampiyonun Karnesi</h2>

    <p>ÃœÃ§ ilaÃ§ arasÄ±nda en dikkat Ã§ekici sonuÃ§larÄ± <strong>tirzepatide</strong> gÃ¶sterdi. Bu ilacÄ± diÄŸerlerinden ayÄ±ran temel Ã¶zellik, hem GLP-1 hem de GIP (glukoza baÄŸÄ±mlÄ± insÃ¼linotropik polipeptid) reseptÃ¶rlerini aktive eden <strong>Ã§ift agonist</strong> yapÄ±sÄ±dÄ±r.</p>

    <div class="key-stat accent anim-slide-up">
      <span class="ks-num">%16</span>
      <span class="ks-text">Tirzepatide kullananlarÄ±n 12-18 ay sonunda ortalama vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ± kaybÄ± â€” plaseboya kÄ±yasla. Bu etki 3,5 yÄ±la kadar sÃ¼rdÃ¼rÃ¼lebilir gÃ¶rÃ¼nÃ¼yor. ğŸŸ¢ (Cochrane sistematik derleme, 8 RKÃ‡, n=6.361)</span>
    </div>

    <p>Cochrane derlemesine dahil edilen <strong>8 randomize kontrollÃ¼ Ã§alÄ±ÅŸma</strong>, toplamda 6.361 katÄ±lÄ±mcÄ±yÄ± kapsamaktadÄ±r. Bulgular oldukÃ§a tutarlÄ±: tirzepatide, plaseboya kÄ±yasla anlamlÄ± derecede Ã¼stÃ¼n kilo kaybÄ± saÄŸlamaktadÄ±r.</p>

    <p>Ancak araÅŸtÄ±rmacÄ±lar Ã¶nemli bir uyarÄ±da bulunuyor: <strong>uzun vadeli gÃ¼venlik verisi hÃ¢lÃ¢ sÄ±nÄ±rlÄ±</strong>. Tirzepatide nispeten yeni bir ilaÃ§ olduÄŸundan (FDA onayÄ± 2023), 5-10 yÄ±llÄ±k yan etki verileri henÃ¼z mevcut deÄŸil.</p>

    <!-- ==================== BÃ–LÃœM 4 ==================== -->
    <h2 id="bolum-4">4. Semaglutide: En Ã‡ok Veri, En Ã‡ok Deneyim</h2>

    <p>Semaglutide, Ã¼Ã§ ilaÃ§ arasÄ±nda <strong>en geniÅŸ kanÄ±t tabanÄ±na</strong> sahip olanÄ±dÄ±r. 18 randomize kontrollÃ¼ Ã§alÄ±ÅŸma ve yaklaÅŸÄ±k 28.000 katÄ±lÄ±mcÄ± ile deÄŸerlendirilmiÅŸtir.</p>

    <!-- SVG Infographic: Semaglutide Weight Loss Timeline -->
    <figure class="blog-infographic anim-slide-up">
      <svg viewBox="0 0 700 280" xmlns="http://www.w3.org/2000/svg">
        <!-- Background -->
        <rect x="0" y="0" width="700" height="280" rx="12" fill="#f8fafc"/>
        <!-- Title -->
        <text x="350" y="30" text-anchor="middle" font-family="Inter, sans-serif" font-size="15" font-weight="700" fill="#0D7377">Semaglutide ile Kilo KaybÄ± SÃ¼reci (Cochrane Verisi)</text>
        <!-- Axis -->
        <line x1="80" y1="240" x2="660" y2="240" stroke="#cbd5e1" stroke-width="1.5"/>
        <line x1="80" y1="50" x2="80" y2="240" stroke="#cbd5e1" stroke-width="1.5"/>
        <!-- Y axis labels -->
        <text x="70" y="240" text-anchor="end" font-family="Inter" font-size="11" fill="#64748b">0%</text>
        <text x="70" y="202" text-anchor="end" font-family="Inter" font-size="11" fill="#64748b">-3%</text>
        <text x="70" y="164" text-anchor="end" font-family="Inter" font-size="11" fill="#64748b">-6%</text>
        <text x="70" y="126" text-anchor="end" font-family="Inter" font-size="11" fill="#64748b">-9%</text>
        <text x="70" y="88" text-anchor="end" font-family="Inter" font-size="11" fill="#64748b">-12%</text>
        <!-- Grid lines -->
        <line x1="80" y1="202" x2="660" y2="202" stroke="#e2e8f0" stroke-width="0.5" stroke-dasharray="4"/>
        <line x1="80" y1="164" x2="660" y2="164" stroke="#e2e8f0" stroke-width="0.5" stroke-dasharray="4"/>
        <line x1="80" y1="126" x2="660" y2="126" stroke="#e2e8f0" stroke-width="0.5" stroke-dasharray="4"/>
        <line x1="80" y1="88" x2="660" y2="88" stroke="#e2e8f0" stroke-width="0.5" stroke-dasharray="4"/>
        <!-- Semaglutide curve -->
        <path d="M80,240 C150,230 200,195 270,170 C340,145 400,110 480,100 C540,94 600,92 660,90" fill="none" stroke="#0D7377" stroke-width="3" stroke-linecap="round"/>
        <!-- Placebo curve -->
        <path d="M80,240 C150,238 200,234 270,232 C340,230 400,228 480,226 C540,225 600,224 660,224" fill="none" stroke="#94a3b8" stroke-width="2" stroke-dasharray="6,4" stroke-linecap="round"/>
        <!-- Data points semaglutide -->
        <circle cx="270" cy="170" r="5" fill="#0D7377"/>
        <circle cx="480" cy="100" r="5" fill="#0D7377"/>
        <circle cx="660" cy="90" r="6" fill="#0D7377" stroke="white" stroke-width="2"/>
        <!-- Labels -->
        <text x="270" y="160" text-anchor="middle" font-family="Inter" font-size="11" font-weight="700" fill="#0D7377">-5.5%</text>
        <text x="480" y="88" text-anchor="middle" font-family="Inter" font-size="11" font-weight="700" fill="#0D7377">-12.4%</text>
        <text x="660" y="78" text-anchor="middle" font-family="Inter" font-size="12" font-weight="800" fill="#0D7377">-14.9%</text>
        <!-- X axis labels -->
        <text x="80" y="258" text-anchor="middle" font-family="Inter" font-size="11" fill="#64748b">BaÅŸlangÄ±Ã§</text>
        <text x="270" y="258" text-anchor="middle" font-family="Inter" font-size="11" fill="#64748b">24 Hafta</text>
        <text x="480" y="258" text-anchor="middle" font-family="Inter" font-size="11" fill="#64748b">52 Hafta</text>
        <text x="660" y="258" text-anchor="middle" font-family="Inter" font-size="11" fill="#64748b">68 Hafta</text>
        <!-- Legend -->
        <rect x="200" y="268" width="14" height="4" rx="2" fill="#0D7377"/>
        <text x="220" y="273" font-family="Inter" font-size="10" fill="#475569">Semaglutide 2.4mg</text>
        <line x1="340" y1="271" x2="354" y2="271" stroke="#94a3b8" stroke-width="2" stroke-dasharray="4,3"/>
        <text x="360" y="273" font-family="Inter" font-size="10" fill="#475569">Plasebo</text>
      </svg>
      <figcaption>Kaynak: STEP-1 Ã§alÄ±ÅŸmasÄ± (Wilding et al., NEJM 2021) â€” Semaglutide 2.4mg, n=1.961. Cochrane tÃ¼m dozlarÄ± havuzladÄ±ÄŸÄ±nda ortalama ~%11'dir.</figcaption>
    </figure>

    <p>Cochrane derlemesi ÅŸu temel bulgularÄ± ortaya koydu:</p>

    <ul>
      <li><strong>Ortalama kilo kaybÄ±:</strong> TÃ¼m dozlar havuzlanmÄ±ÅŸ meta-analizde ~%11 (plaseboya kÄ±yasla) ğŸŸ¢ (Cochrane meta-analiz, 18 RKÃ‡, n=27.949). Obezite dozu olan 2.4mg semaglutide ile STEP-1 Ã§alÄ±ÅŸmasÄ±nda bu oran %14.9'a ulaÅŸmÄ±ÅŸtÄ±r (68 hafta) ğŸŸ¢ (STEP-1, RKÃ‡, n=1.961)</li>
      <li><strong>â‰¥%5 kilo kaybÄ± oranÄ±:</strong> Semaglutide grubunda anlamlÄ± ÅŸekilde daha yÃ¼ksek</li>
      <li><strong>Etki sÃ¼resi:</strong> 2 yÄ±la kadar sÃ¼rdÃ¼rÃ¼lebilir</li>
      <li><strong>Gastrointestinal yan etkiler:</strong> Plaseboya kÄ±yasla daha sÄ±k (bulantÄ±, kusma, ishal)</li>
      <li><strong>KardiyovaskÃ¼ler sonuÃ§lar:</strong> Cochrane derlemesindeki obezite Ã§alÄ±ÅŸmalarÄ±nda kesin MACE sonucu bildirilmemiÅŸtir; ancak <em>ayrÄ± bir Ã§alÄ±ÅŸma olan</em> SELECT (2023, n=17.604) semaglutide 2.4mg ile MACE'de %20 azalma gÃ¶stermiÅŸtir (HR 0.80, %95 GA 0.72-0.90) ğŸŸ¢ (SELECT, RKÃ‡, n=17.604)</li>
      <li><strong>YaÅŸam kalitesi:</strong> STEP alt Ã§alÄ±ÅŸmalarÄ±nda semaglutide ile yaÅŸam kalitesinde iyileÅŸme bildirilmiÅŸtir (IWQOL-Lite Ã¶lÃ§eÄŸi)</li>
    </ul>

    <blockquote class="blog-quote anim-slide-up">
      Bu ilaÃ§lar, Ã¶zellikle ilk yÄ±lda ciddi kilo kaybÄ± saÄŸlama potansiyeline sahip. Obezite ile yaÅŸayan insanlar iÃ§in etkili tedavi arayÄ±ÅŸÄ±nda onlarca yÄ±l sonra bu heyecan verici bir an.
      <cite>â€” Juan Franco, Cochrane Derleme BaÅŸ AraÅŸtÄ±rmacÄ±sÄ±, Heinrich Heine Ãœniversitesi DÃ¼sseldorf</cite>
    </blockquote>

    <!-- ==================== BÃ–LÃœM 5 ==================== -->
    <h2 id="bolum-5">5. Liraglutide: Ä°lk KuÅŸaÄŸÄ±n Dersleri</h2>

    <p>GLP-1 ailesinin "bÃ¼yÃ¼k abisi" olan liraglutide, 2014'ten bu yana obezite tedavisinde kullanÄ±lmaktadÄ±r. 24 Ã§alÄ±ÅŸma ve yaklaÅŸÄ±k 10.000 katÄ±lÄ±mcÄ±yla deÄŸerlendirildi.</p>

    <div class="key-stat anim-slide-up">
      <span class="ks-num">%5-8</span>
      <span class="ks-text">Liraglutide ile tÃ¼m dozlarÄ±n havuzlanmÄ±ÅŸ ortalama kilo kaybÄ±. Obezite dozu olan 3.0mg'da (Saxenda) SCALE Ã§alÄ±ÅŸmasÄ±nda plasebo-ayarlÄ± kayÄ±p ~%8'e ulaÅŸmaktadÄ±r; dÃ¼ÅŸÃ¼k dozlar (1.8mg, diyabet endikasyonu) dahil edildiÄŸinde ortalama dÃ¼ÅŸer. ğŸŸ¢ (Cochrane sistematik derleme, 24 RKÃ‡, n=9.937)</span>
    </div>

    <p>Liraglutide'in gÃ¼nlÃ¼k enjeksiyon gerektirmesi ve daha dÃ¼ÅŸÃ¼k etkinliÄŸi, onu yeni nesil haftalÄ±k enjeksiyonlara kÄ±yasla dezavantajlÄ± bir konuma getirmektedir. Ancak bu ilacÄ±n en bÃ¼yÃ¼k avantajÄ±, <strong>en uzun klinik deneyime</strong> sahip GLP-1 olmasÄ±dÄ±r â€” 10 yÄ±lÄ± aÅŸkÄ±n gerÃ§ek dÃ¼nya verisi bulunmaktadÄ±r.</p>

    <!-- SVG Infographic: 3 Ä°laÃ§ KarÅŸÄ±laÅŸtÄ±rma Bar Chart -->
    <figure class="blog-infographic anim-slide-up">
      <svg viewBox="0 0 700 320" xmlns="http://www.w3.org/2000/svg">
        <!-- Background -->
        <rect x="0" y="0" width="700" height="320" rx="12" fill="#f8fafc"/>
        <!-- Title -->
        <text x="350" y="32" text-anchor="middle" font-family="Inter, sans-serif" font-size="15" font-weight="700" fill="#0D7377">GLP-1 Ä°laÃ§larÄ±: Kilo KaybÄ± KarÅŸÄ±laÅŸtÄ±rmasÄ± (Cochrane 2026)</text>
        <text x="350" y="50" text-anchor="middle" font-family="Inter" font-size="11" fill="#94a3b8">Plaseboya kÄ±yasla ortalama vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ± deÄŸiÅŸimi (%)</text>

        <!-- Bars -->
        <!-- Tirzepatide -->
        <rect x="100" y="80" width="160" height="160" rx="10" fill="url(#grad-tirz)" opacity="0.9"/>
        <text x="180" y="130" text-anchor="middle" font-family="Inter" font-size="42" font-weight="800" fill="white">%16</text>
        <text x="180" y="155" text-anchor="middle" font-family="Inter" font-size="12" font-weight="500" fill="rgba(255,255,255,0.85)">12-18 ay</text>
        <text x="180" y="260" text-anchor="middle" font-family="Inter" font-size="14" font-weight="700" fill="#195157">Tirzepatide</text>
        <text x="180" y="278" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">8 RKÃ‡ Â· 6.361 kiÅŸi</text>
        <text x="180" y="293" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">GLP-1 + GIP Ã§ift agonist</text>

        <!-- Semaglutide -->
        <rect x="280" y="110" width="160" height="130" rx="10" fill="url(#grad-sema)" opacity="0.9"/>
        <text x="360" y="155" text-anchor="middle" font-family="Inter" font-size="42" font-weight="800" fill="white">%11</text>
        <text x="360" y="180" text-anchor="middle" font-family="Inter" font-size="12" font-weight="500" fill="rgba(255,255,255,0.85)">24-68 hafta</text>
        <text x="360" y="260" text-anchor="middle" font-family="Inter" font-size="14" font-weight="700" fill="#195157">Semaglutide</text>
        <text x="360" y="278" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">18 RKÃ‡ Â· 27.949 kiÅŸi</text>
        <text x="360" y="293" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">GLP-1 agonist</text>

        <!-- Liraglutide -->
        <rect x="460" y="165" width="160" height="75" rx="10" fill="url(#grad-lira)" opacity="0.9"/>
        <text x="540" y="210" text-anchor="middle" font-family="Inter" font-size="30" font-weight="800" fill="white">%5-8</text>
        <text x="540" y="260" text-anchor="middle" font-family="Inter" font-size="14" font-weight="700" fill="#195157">Liraglutide</text>
        <text x="540" y="278" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">24 RKÃ‡ Â· 9.937 kiÅŸi</text>
        <text x="540" y="293" text-anchor="middle" font-family="Inter" font-size="10" fill="#64748b">GLP-1 agonist (1. kuÅŸak)</text>

        <!-- Gradients -->
        <defs>
          <linearGradient id="grad-tirz" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#E8963E"/>
            <stop offset="100%" stop-color="#D4762A"/>
          </linearGradient>
          <linearGradient id="grad-sema" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#0D7377"/>
            <stop offset="100%" stop-color="#095558"/>
          </linearGradient>
          <linearGradient id="grad-lira" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#6B7280"/>
            <stop offset="100%" stop-color="#4B5563"/>
          </linearGradient>
        </defs>
      </svg>
      <figcaption>Kaynak: WHO Cochrane Sistematik Derlemeleri, 2026. Her ilaÃ§ iÃ§in ayrÄ± meta-analiz sonuÃ§larÄ±.</figcaption>
    </figure>

    <!-- ==================== BÃ–LÃœM 6 ==================== -->
    <h2 id="bolum-6">6. Yan Etkiler ve GÃ¼venlik Profili</h2>

    <p>Cochrane derlemeleri, GLP-1 ilaÃ§larÄ±nÄ±n yan etki profilini de detaylÄ± biÃ§imde analiz etti. ÃœÃ§ ilaÃ§ grubu iÃ§in de en sÄ±k karÅŸÄ±laÅŸÄ±lan yan etkiler <strong>gastrointestinal</strong> sorunlardÄ±r.</p>

    <div class="bar-chart anim-slide-up">
      <h4>ğŸ“Š En SÄ±k Bildirilen Yan Etkiler (Semaglutide 2.4mg, STEP-1 verileri)</h4>
      <div class="bar-row">
        <span class="bar-label">BulantÄ±</span>
        <div class="bar-track"><div class="bar-fill clr-accent" style="width:44%">%44</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Ä°shal</span>
        <div class="bar-track"><div class="bar-fill clr-primary" style="width:32%">%32</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Kusma</span>
        <div class="bar-track"><div class="bar-fill clr-dark" style="width:25%">%25</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">KabÄ±zlÄ±k</span>
        <div class="bar-track"><div class="bar-fill clr-gray" style="width:20%">%20</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">KarÄ±n aÄŸrÄ±sÄ±</span>
        <div class="bar-track"><div class="bar-fill clr-success" style="width:15%">%15</div></div>
      </div>
    </div>

    <p>Bu yan etkiler genellikle <strong>hafif-orta ÅŸiddette</strong> olup, tedavinin ilk haftalarÄ±nda ortaya Ã§Ä±kÄ±p zamanla azalma eÄŸilimi gÃ¶stermektedir. Ancak bazÄ± katÄ±lÄ±mcÄ±lar yan etkiler nedeniyle tedaviyi bÄ±rakmÄ±ÅŸtÄ±r.</p>

    <div class="blog-box warning anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M10.29 3.86L1.82 18a2 2 0 001.71 3h16.94a2 2 0 001.71-3L13.71 3.86a2 2 0 00-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>
      <div class="box-body">
        <strong>Ã–nemli KanÄ±t BoÅŸluklarÄ±</strong>
        <ul>
          <li>Cochrane obezite derlemesinde MACE sonuÃ§larÄ± kesin deÄŸildir; ancak SELECT Ã§alÄ±ÅŸmasÄ± (derleme dÄ±ÅŸÄ±) semaglutide ile %20 KV olay azalmasÄ± gÃ¶stermiÅŸtir â€” tirzepatide ve liraglutide iÃ§in eÅŸdeÄŸer bÃ¼yÃ¼k KV sonlanÄ±m Ã§alÄ±ÅŸmasÄ± henÃ¼z yoktur</li>
          <li>TÃ¼m nedenlere baÄŸlÄ± Ã¶lÃ¼m oranlarÄ±nda anlamlÄ± azalma gÃ¶sterilmemiÅŸtir; yaÅŸam kalitesi verileri sÄ±nÄ±rlÄ± deÄŸerlendirilmiÅŸtir</li>
          <li>5 yÄ±lÄ±n Ã¼zerinde uzun vadeli gÃ¼venlik verisi hiÃ§bir ilaÃ§ iÃ§in yeterli deÄŸildir</li>
          <li>Ä°laÃ§ kesildikten sonra kilo geri alÄ±mÄ± konusunda sistematik veri sÄ±nÄ±rlÄ±dÄ±r</li>
        </ul>
      </div>
    </div>

    <h3>Ä°laÃ§ Kesildikten Sonra Ne Oluyor?</h3>

    <p>Bu belki de en kritik sorulardan biri. Mevcut kanÄ±tlar, GLP-1 ilaÃ§larÄ±nÄ±n <strong>tedavi sÃ¼resince</strong> etkili olduÄŸunu gÃ¶stermektedir. Ancak ilaÃ§ kesildiÄŸinde kilo geri alÄ±mÄ±nÄ±n yaÅŸanÄ±p yaÅŸanmadÄ±ÄŸÄ± konusunda yeterli uzun vadeli randomize kontrollÃ¼ Ã§alÄ±ÅŸma bulunmamaktadÄ±r.</p>

    <p>BazÄ± gÃ¶zlemsel veriler, tedavi sonlandÄ±rÄ±ldÄ±ÄŸÄ±nda hastalarÄ±n kaybettikleri kilonun Ã¶nemli bir kÄ±smÄ±nÄ± geri aldÄ±ÄŸÄ±nÄ± dÃ¼ÅŸÃ¼ndÃ¼rmektedir â€” bu da GLP-1 tedavisinin kronik (sÃ¼resiz) kullanÄ±m gerektirebileceÄŸi anlamÄ±na gelmektedir.</p>

    <!-- ==================== BÃ–LÃœM 7 ==================== -->
    <h2 id="bolum-7">7. EndÃ¼stri SponsorluÄŸu: Filin Odadaki GÃ¶lgesi</h2>

    <p>Cochrane derlemelerinin en Ã§arpÄ±cÄ± bulgularÄ±ndan biri, incelenen Ã§alÄ±ÅŸmalardaki <strong>endÃ¼stri katÄ±lÄ±mÄ±nÄ±n boyutu</strong> oldu. Bu, bilimsel bulgularÄ±n gÃ¼venilirliÄŸi aÃ§Ä±sÄ±ndan Ã¶nemli bir tartÄ±ÅŸma noktasÄ± oluÅŸturmaktadÄ±r.</p>

    <div class="key-stat danger anim-slide-up">
      <span class="ks-num">âš ï¸</span>
      <span class="ks-text">Ä°ncelenen Ã§alÄ±ÅŸmalarÄ±n bÃ¼yÃ¼k Ã§oÄŸunluÄŸu, ilacÄ± Ã¼reten firmalar tarafÄ±ndan finanse edilmiÅŸ, tasarlanmÄ±ÅŸ, yÃ¼rÃ¼tÃ¼lmÃ¼ÅŸ ve raporlanmÄ±ÅŸtÄ±r. Bu dÃ¼zeyde endÃ¼stri katÄ±lÄ±mÄ±, potansiyel Ã§Ä±kar Ã§atÄ±ÅŸmasÄ± endiÅŸesi doÄŸurmaktadÄ±r.</span>
    </div>

    <p>Peki endÃ¼stri sponsorluÄŸu neden sorun?</p>

    <ul>
      <li><strong>YayÄ±n yanlÄ±lÄ±ÄŸÄ± (publication bias):</strong> Olumsuz sonuÃ§lu Ã§alÄ±ÅŸmalarÄ±n yayÄ±nlanmama riski</li>
      <li><strong>Ã‡alÄ±ÅŸma tasarÄ±mÄ±:</strong> Firma, ilacÄ±n en iyi gÃ¶rÃ¼ndÃ¼ÄŸÃ¼ koÅŸullarÄ± seÃ§ebilir</li>
      <li><strong>SonuÃ§ Ã¶lÃ§Ã¼tÃ¼ seÃ§imi:</strong> Primer endpoint'ler firmanÄ±n lehine belirlenebilir</li>
      <li><strong>Veri eriÅŸimi:</strong> Ham veriler baÄŸÄ±msÄ±z araÅŸtÄ±rmacÄ±lara her zaman aÃ§Ä±k olmayabilir</li>
    </ul>

    <div class="blog-box tip anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M12 2L2 7l10 5 10-5-10-5z"/><path d="M2 17l10 5 10-5"/><path d="M2 12l10 5 10-5"/></svg>
      <div class="box-body">
        <strong>BaÄŸÄ±msÄ±z AraÅŸtÄ±rma Neden Ã–nemli?</strong>
        <p>Cochrane araÅŸtÄ±rmacÄ±larÄ±, GLP-1 ilaÃ§larÄ±nÄ±n gerÃ§ek dÃ¼nya etkinliÄŸini ve gÃ¼venliÄŸini doÄŸrulamak iÃ§in <strong>endÃ¼striden baÄŸÄ±msÄ±z, uzun sÃ¼reli randomize kontrollÃ¼ Ã§alÄ±ÅŸmalara</strong> acil ihtiyaÃ§ olduÄŸunu vurgulamaktadÄ±r. Mevcut kanÄ±tlarÄ±n Ã§oÄŸu ilaÃ§ firmalarÄ±nÄ±n kontrolÃ¼nde Ã¼retilmiÅŸtir.</p>
      </div>
    </div>

    <p>Bu durum, GLP-1 ilaÃ§larÄ±nÄ±n etkisiz olduÄŸu anlamÄ±na gelmez â€” Cochrane derlemeleri etkinliÄŸi aÃ§Ä±kÃ§a doÄŸrulamÄ±ÅŸtÄ±r. Ancak etki bÃ¼yÃ¼klÃ¼klerinin abartÄ±lmÄ±ÅŸ olup olmadÄ±ÄŸÄ±, yan etkilerin tam olarak raporlanÄ±p raporlanmadÄ±ÄŸÄ± ve uzun vadeli risk-fayda dengesinin ne olduÄŸu konularÄ±nda <strong>baÄŸÄ±msÄ±z doÄŸrulama</strong> gereklidir.</p>

    <!-- ==================== BÃ–LÃœM 8 ==================== -->
    <h2 id="bolum-8">8. TÃ¼rkiye'de Durum Ne?</h2>

    <p>Cochrane verilerini TÃ¼rkiye baÄŸlamÄ±nda deÄŸerlendirmek Ã¶nemlidir. Ãœlkemizde GLP-1 ilaÃ§larÄ±nÄ±n eriÅŸimi ve kullanÄ±mÄ±, kÃ¼resel tablodan farklÄ± dinamikler taÅŸÄ±maktadÄ±r.</p>

    <div class="blog-box info anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="16" x2="12" y2="12"/><line x1="12" y1="8" x2="12.01" y2="8"/></svg>
      <div class="box-body">
        <strong>ğŸ‡¹ğŸ‡· TÃ¼rkiye'ye Ã–zel Notlar</strong>
        <ul>
          <li>TÃ¼rkiye'de yetiÅŸkin obezite oranÄ± <strong>%32</strong> civarÄ±ndadÄ±r (OECD ortalamasÄ±nÄ±n Ã¼zerinde) ğŸŸ¡ (OECD/TÃœÄ°K, gÃ¶zlemsel veri, 2024)</li>
          <li>Semaglutide TÃ¼rkiye'de diyabet endikasyonuyla (Ozempic, 1.0mg) TÄ°TCK onaylÄ±dÄ±r; obezite dozu (Wegovy, 2.4mg) henÃ¼z ayrÄ± onay almamÄ±ÅŸtÄ±r. SGK geri Ã¶demesi sÄ±nÄ±rlÄ±dÄ±r</li>
          <li>Tirzepatide henÃ¼z TÃ¼rkiye'de yaygÄ±n kullanÄ±mda deÄŸildir</li>
          <li>AylÄ±k ilaÃ§ maliyeti hastalarÄ±n bÃ¼yÃ¼k Ã§oÄŸunluÄŸu iÃ§in eriÅŸilebilir dÃ¼zeyde deÄŸildir</li>
          <li>KaÃ§ak ve sahte ilaÃ§ riski ciddi bir halk saÄŸlÄ±ÄŸÄ± sorunu oluÅŸturmaktadÄ±r</li>
        </ul>
      </div>
    </div>

    <p>WHO'nun hazÄ±rlayacaÄŸÄ± yeni kÄ±lavuzlar, TÃ¼rkiye gibi Ã¼lkeler iÃ§in Ã¶zellikle Ã¶nemlidir. Bu kÄ±lavuzlar, <strong>maliyet-etkinlik analizleri</strong> ve <strong>eriÅŸim eÅŸitliÄŸi</strong> ilkeleri doÄŸrultusunda, hangi hasta gruplarÄ±nÄ±n GLP-1 tedavisinden en Ã§ok fayda gÃ¶receÄŸini ve sÄ±nÄ±rlÄ± kaynaklarÄ±n nasÄ±l daÄŸÄ±tÄ±lacaÄŸÄ±nÄ± belirleyecektir.</p>

    <p>Cochrane araÅŸtÄ±rmacÄ±larÄ± da bu konuya dikkat Ã§ekerek, GLP-1 ilaÃ§larÄ±nÄ±n yaygÄ±nlaÅŸtÄ±rÄ±lmasÄ±nÄ±n <strong>sosyal ve ticari saÄŸlÄ±k belirleyicilerini</strong> â€” maliyet, sigorta kapsamÄ± ve genel eriÅŸim â€” dikkate almasÄ± gerektiÄŸini vurgulamaktadÄ±r. Aksi takdirde bu ilaÃ§lar, mevcut saÄŸlÄ±k eÅŸitsizliklerini derinleÅŸtirebilir.</p>

    <!-- ==================== BÃ–LÃœM 9 ==================== -->
    <h2 id="bolum-9">9. SonuÃ§: Ne AnlamamÄ±z Gerekiyor?</h2>

    <p>WHO'nun yaptÄ±rdÄ±ÄŸÄ± Cochrane derlemeleri, GLP-1 ilaÃ§larÄ± hakkÄ±nda ÅŸimdiye kadarki en kapsamlÄ± ve en gÃ¼venilir baÄŸÄ±msÄ±z deÄŸerlendirmeyi sunmaktadÄ±r. Bulgular net bir tablo Ã§iziyor:</p>

    <!-- Key Takeaway -->
    <div class="blog-takeaway anim-slide-up">
      <h4>ğŸ¯ Ana Ã‡Ä±karÄ±mlar</h4>
      <ul>
        <li>GLP-1 ilaÃ§larÄ± anlamlÄ± kilo kaybÄ± saÄŸlÄ±yor â€” tirzepatide ~%16, semaglutide ~%11 (tÃ¼m dozlar havuzlanmÄ±ÅŸ; 2.4mg ile ~%15), liraglutide ~%5-8 (3.0mg ile ~%8) ğŸŸ¢ (Cochrane sistematik derlemeleri, 2026)</li>
        <li>Etki tedavi sÃ¼resince devam ediyor ancak ilaÃ§ kesilince geri dÃ¶nÃ¼ÅŸ riski yÃ¼ksek</li>
        <li>Yan etkiler Ã§oÄŸunlukla hafif-orta dÃ¼zeyde, gastrointestinal yakÄ±nmalar Ã¶n planda</li>
        <li>SELECT Ã§alÄ±ÅŸmasÄ± semaglutide ile %20 KV olay azalmasÄ± gÃ¶sterdi ğŸŸ¢ (SELECT, RKÃ‡, n=17.604); ancak tirzepatide/liraglutide iÃ§in benzer KV sonlanÄ±m verisi henÃ¼z yok</li>
        <li>Ã‡alÄ±ÅŸmalarÄ±n bÃ¼yÃ¼k Ã§oÄŸunluÄŸu endÃ¼stri sponsorlu â€” baÄŸÄ±msÄ±z doÄŸrulama ÅŸart</li>
        <li>Uzun vadeli (5+ yÄ±l) gÃ¼venlik verisi kritik derecede eksik</li>
        <li>EriÅŸim eÅŸitsizliÄŸi ciddi bir kÃ¼resel sorun olmaya devam ediyor</li>
      </ul>
    </div>

    <p>Bu derlemeler, GLP-1 ilaÃ§larÄ±nÄ± ne yÃ¼celtiyor ne de karalÄ±yor. <strong>KanÄ±tÄ±n ne sÃ¶ylediÄŸini ve ne sÃ¶ylemediÄŸini</strong> aÃ§Ä±kÃ§a ortaya koyuyor. Ve bilim tam da bÃ¶yle Ã§alÄ±ÅŸÄ±r.</p>

    <p>EÄŸer GLP-1 ilaÃ§larÄ±nÄ± kullanmayÄ± dÃ¼ÅŸÃ¼nÃ¼yorsanÄ±z veya halihazÄ±rda kullanÄ±yorsanÄ±z, bu derlemelerin size mesajÄ± ÅŸudur: <strong>Bu ilaÃ§lar etkili araÃ§lardÄ±r, ancak sihirli deÄŸnek deÄŸildir.</strong> Her tedavi kararÄ±, doktorunuzla birlikte, kiÅŸisel risk faktÃ¶rleriniz, yaÅŸam tarzÄ±nÄ±z ve beklentileriniz deÄŸerlendirilerek alÄ±nmalÄ±dÄ±r.</p>

    <div class="blog-box success anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M22 11.08V12a10 10 0 11-5.93-9.14"/><polyline points="22 4 12 14.01 9 11.01"/></svg>
      <div class="box-body">
        <strong>UzunYaÅŸa'nÄ±n YaklaÅŸÄ±mÄ±</strong>
        <p>Biz her zaman <strong>kanÄ±ta dayalÄ±, baÄŸÄ±msÄ±z ve hasta merkezli</strong> bilgi sunmayÄ± ilke ediniriz. GLP-1 ilaÃ§larÄ± obezite tedavisinde Ã¶nemli bir araÃ§tÄ±r, ancak beslenme, egzersiz, uyku ve psikolojik destek gibi yaÅŸam tarzÄ± mÃ¼dahaleleri tedavinin temelini oluÅŸturmaya devam etmektedir.</p>
      </div>
    </div>

  </div>

  <!-- Social Sharing -->
  <div class="blog-share">
    <span>PaylaÅŸ:</span>
    <a class="share-btn" href="https://twitter.com/intent/tweet?url=https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html&text=WHO%20Cochrane%20%C4%B0ncelemesi%3A%20GLP-1%20%C4%B0la%C3%A7lar%C4%B1%20Ger%C3%A7ekten%20Ne%20Kadar%20Etkili%3F" target="_blank" rel="noopener" aria-label="Twitter'da paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"/></svg>
    </a>
    <a class="share-btn" href="https://www.linkedin.com/sharing/share-offsite/?url=https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html" target="_blank" rel="noopener" aria-label="LinkedIn'de paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433a2.062 2.062 0 01-2.063-2.065 2.064 2.064 0 112.063 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"/></svg>
    </a>
    <a class="share-btn" href="https://wa.me/?text=WHO%20Cochrane%20%C4%B0ncelemesi%3A%20GLP-1%20%C4%B0la%C3%A7lar%C4%B1%20Ne%20Kadar%20Etkili%3F%20https://uzunyasa.com/pages/blog/who-cochrane-glp1-incelemesi.html" target="_blank" rel="noopener" aria-label="WhatsApp'ta paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M17.472 14.382c-.297-.149-1.758-.867-2.03-.967-.273-.099-.471-.148-.67.15-.197.297-.767.966-.94 1.164-.173.199-.347.223-.644.075-.297-.15-1.255-.463-2.39-1.475-.883-.788-1.48-1.761-1.653-2.059-.173-.297-.018-.458.13-.606.134-.133.298-.347.446-.52.149-.174.198-.298.298-.497.099-.198.05-.371-.025-.52-.075-.149-.669-1.612-.916-2.207-.242-.579-.487-.5-.669-.51-.173-.008-.371-.01-.57-.01-.198 0-.52.074-.792.372-.272.297-1.04 1.016-1.04 2.479 0 1.462 1.065 2.875 1.213 3.074.149.198 2.096 3.2 5.077 4.487.709.306 1.262.489 1.694.625.712.227 1.36.195 1.871.118.571-.085 1.758-.719 2.006-1.413.248-.694.248-1.289.173-1.413-.074-.124-.272-.198-.57-.347m-5.421 7.403h-.004a9.87 9.87 0 01-5.031-1.378l-.361-.214-3.741.982.998-3.648-.235-.374a9.86 9.86 0 01-1.51-5.26c.001-5.45 4.436-9.884 9.888-9.884 2.64 0 5.122 1.03 6.988 2.898a9.825 9.825 0 012.893 6.994c-.003 5.45-4.437 9.884-9.885 9.884m8.413-18.297A11.815 11.815 0 0012.05 0C5.495 0 .16 5.335.157 11.892c0 2.096.547 4.142 1.588 5.945L.057 24l6.305-1.654a11.882 11.882 0 005.683 1.448h.005c6.554 0 11.89-5.335 11.893-11.893a11.821 11.821 0 00-3.48-8.413z"/></svg>
    </a>
  </div>

  <!-- Author Box -->
  <div class="blog-author anim-slide-up">
    <div class="blog-author-avatar">UY</div>
    <div class="blog-author-info">
      <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
      <p>TÄ±bbi Ä°nceleme: Endokrinoloji ve Ä°Ã§ HastalÄ±klarÄ± UzmanlarÄ± DanÄ±ÅŸma Kurulu</p>
    </div>
  </div>

  <!-- CTA -->
  <div class="blog-cta anim-slide-up">
    <h3>Kilo yÃ¶netimi yolculuÄŸunuza baÅŸlayÄ±n</h3>
    <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in Ã¼cretsiz testimizi tamamlayÄ±n</p>
    <a href="../test.html">Teste BaÅŸla â†’</a>
  </div>

  <!-- Related Posts -->
  <div class="blog-related anim-slide-up">
    <h3>ğŸ“š Ä°lgili YazÄ±lar</h3>
    <div class="related-grid">
      <a href="glp1-nedir-rehber.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1559757175-5700dde675bc?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>GLP-1 Nedir? KapsamlÄ± Rehber</h4>
          <p>10 dk okuma â€¢ Ocak 2026</p>
        </div>
      </a>
      <a href="fda-kopya-glp1-yasaklari-v2.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>FDA Kopya GLP-1 YasaklarÄ±</h4>
          <p>8 dk okuma â€¢ Ocak 2026</p>
        </div>
      </a>
      <a href="bariatrik-cerrahi-rehberi.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1551076805-e1869033e561?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>Bariatrik Cerrahi Rehberi</h4>
          <p>12 dk okuma â€¢ AralÄ±k 2025</p>
        </div>
      </a>
    </div>
  </div>

  <!-- Newsletter -->
  <div class="blog-newsletter anim-slide-up">
    <h3>ğŸ“¬ SaÄŸlÄ±k BÃ¼ltenimize KatÄ±lÄ±n</h3>
    <p>HaftanÄ±n en Ã¶nemli saÄŸlÄ±k haberleri ve bilimsel geliÅŸmeleri e-postanÄ±za gelsin.</p>
    <form class="newsletter-form" onsubmit="return false;">
      <input type="email" placeholder="E-posta adresiniz" required>
      <button type="submit">Abone Ol</button>
    </form>
  </div>

  <!-- Disclaimer -->
  <div class="blog-disclaimer">
    <strong>Yasal UyarÄ±:</strong> Bu yazÄ± bilgilendirme amaÃ§lÄ±dÄ±r ve tÄ±bbi tavsiye niteliÄŸi taÅŸÄ±maz.
    Tedavi kararlarÄ± iÃ§in mutlaka bir saÄŸlÄ±k profesyoneline danÄ±ÅŸÄ±n.
    <br><br>
    <strong>Kaynaklar:</strong><br>
    1. Franco JVA et al. Tirzepatide for the treatment of obesity (Cochrane Review). <em>Cochrane Database Syst Rev.</em> 2026. WHO-commissioned.<br>
    2. Franco JVA et al. Semaglutide for the treatment of obesity (Cochrane Review). <em>Cochrane Database Syst Rev.</em> 2026. WHO-commissioned.<br>
    3. Franco JVA et al. Liraglutide for the treatment of obesity (Cochrane Review). <em>Cochrane Database Syst Rev.</em> 2026. WHO-commissioned.<br>
    4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). <em>N Engl J Med.</em> 2023;389(24):2221-2232.<br>
    5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). <em>N Engl J Med.</em> 2022;387(3):205-216.<br>
    6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). <em>N Engl J Med.</em> 2021;384(11):989-1002.<br>
    7. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg liraglutide in weight management (SCALE). <em>N Engl J Med.</em> 2015;373(1):11-22.<br>
    8. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity. <em>N Engl J Med.</em> 2025;393(1):26-36.<br>
    9. TÃ¼rkiye Ä°statistik Kurumu (TÃœÄ°K). SaÄŸlÄ±k AraÅŸtÄ±rmasÄ±, 2024.<br>
    10. OECD Health Statistics. Obesity Update, 2025.
  </div>

</article>

<!-- FOOTER -->
<footer class="footer">
  <div class="footer-inner">
    <div class="footer-grid">
      <div class="footer-brand">
        <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="footer-logo">
        <p>TÃ¼rkiye uzun yaÅŸasÄ±n diye. KanÄ±ta dayalÄ± saÄŸlÄ±k bilgisi ve araÃ§larÄ±.</p>
      </div>
      <div class="footer-col">
        <h4>KeÅŸfet</h4>
        <a href="../beslenme.html">Beslenme</a>
        <a href="../egzersiz.html">Egzersiz</a>
        <a href="../tedavi.html">Kilo YÃ¶netimi</a>
        <a href="../uyku-stres.html">Zihin & DavranÄ±ÅŸ</a>
      </div>
      <div class="footer-col">
        <h4>AraÃ§lar</h4>
        <a href="../araclar.html">TÃ¼m AraÃ§lar</a>
        <a href="../test.html">KiÅŸisel Test</a>
        <a href="../blog.html">Blog</a>
      </div>
      <div class="footer-col">
        <h4>HakkÄ±mÄ±zda</h4>
        <a href="../hakkimizda.html">Ekibimiz</a>
        <a href="../bilim.html">Bilim</a>
        <a href="https://tyzd.org" target="_blank">TYZD</a>
      </div>
    </div>
    <div class="footer-bottom">
      <span>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</span>
      <span style="font-size:0.8rem;opacity:0.5;">Bu site tÄ±bbi tavsiye sunmaz. Tedavi iÃ§in doktorunuza danÄ±ÅŸÄ±n.</span>
    </div>
  </div>
</footer>

<!-- Scripts -->
<script>
// Reading Progress Bar
window.addEventListener('scroll', () => {
  const article = document.querySelector('.blog-article');
  if (!article) return;
  const rect = article.getBoundingClientRect();
  const total = article.scrollHeight - window.innerHeight;
  const scrolled = -rect.top;
  const pct = Math.min(Math.max(scrolled / total * 100, 0), 100);
  document.getElementById('blogProgress').style.width = pct + '%';
});

// Scroll Animation Observer
const observer = new IntersectionObserver((entries) => {
  entries.forEach(e => {
    if (e.isIntersecting) {
      e.target.classList.add('anim-visible');
      observer.unobserve(e.target);
    }
  });
}, { threshold: 0.15 });

document.querySelectorAll('.anim-slide-up, .bar-fill').forEach(el => {
  if (!el.classList.contains('anim-visible')) observer.observe(el);
});

// Header scroll effect
let lastScroll = 0;
window.addEventListener('scroll', () => {
  const header = document.querySelector('.header');
  if (window.scrollY > 60) {
    header.classList.add('scrolled');
  } else {
    header.classList.remove('scrolled');
  }
});
</script>
<script src="../../scripts/animations.js" defer></script>
<script src="/scripts/premium-animations.js" defer></script>
</body>
</html>